<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333356</url>
  </required_header>
  <id_info>
    <org_study_id>UC-0160/1617</org_study_id>
    <secondary_id>2016-A01535-46</secondary_id>
    <nct_id>NCT03333356</nct_id>
  </id_info>
  <brief_title>Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)</brief_title>
  <acronym>Bladder-ART</acronym>
  <official_title>Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer: A Randomized Multicentre Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized multicentre study in patients with high-risk MIBC to investigate&#xD;
      adjuvant radiotherapy after radical cystectomy and pelvic lymph node dissection.&#xD;
&#xD;
      The objective of the study is to provide evidence that adjuvant radiotherapy improves&#xD;
      loco-regional control with potential benefits in survival. The study will also evaluate the&#xD;
      quality of life of patients and the tolerance of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      INDICATION:&#xD;
&#xD;
      Patients with pathological high-risk muscle invasive bladder cancer treated by radical&#xD;
      cystectomy and pelvic lymph nodes dissection&#xD;
&#xD;
      METHODOLOGY:&#xD;
&#xD;
      Multicenter randomised phase II study in high-risk bladder cancer patients treated by radical&#xD;
      cystectomy with pelvic lymph nodes dissection assessing :&#xD;
&#xD;
        -  Experimental Arm: adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions&#xD;
           (total dose of 50.4 Gy), 5 days per week, 1 fraction /day (duration of RT is 38 days).&#xD;
&#xD;
        -  Standard Arm: surveillance. Eligible patients will be randomised, in a 3:1 ratio, to&#xD;
           receive either: adjuvant pelvic radiotherapy (Experimental Arm), or surveillance&#xD;
           (Standard Arm).&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      The primary objective of the trial is to assess the efficacy of adjuvant radiotherapy in&#xD;
      patients with high-risk bladder cancer after radical cystectomy and pelvic lymph nodes&#xD;
      dissection. Efficacy will be assessed in terms of pelvic recurrence-free survival (PRFS) at 3&#xD;
      years.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      For each treatment arm (adjuvant pelvic radiotherapy [Experimental Arm], or surveillance&#xD;
      [Standard Arm]), these objectives will be evaluated independently.&#xD;
&#xD;
        -  To evaluate 5-year pelvic recurrence-free survival (PRFS)&#xD;
&#xD;
        -  To evaluate disease-free survival (DFS) at 3 and 5 years.&#xD;
&#xD;
        -  To evaluate overall survival (OS) at 3 and 5 years.&#xD;
&#xD;
        -  To evaluate metastasis-free survival (MFS) at 3 and 5 years.&#xD;
&#xD;
        -  To evaluate disease-specific survival (DSS) at 3 and 5 years.&#xD;
&#xD;
        -  To evaluate the tolerance and safety of each treatment strategy.&#xD;
&#xD;
        -  To evaluate patients' quality of life.&#xD;
&#xD;
      Ancillary studies Objectives:&#xD;
&#xD;
        -  Investigation of individual predisposition to develop radiotherapy induced late&#xD;
           digestive toxicity using the radiation-induced lymphocyte apoptosis (RILA) assay&#xD;
&#xD;
        -  The analyse of genomic and transcriptome correlation between different clusters and&#xD;
           oncological outcomes&#xD;
&#xD;
        -  Dosimetric banking to evaluate the correlation of Dose-Volume Histogram with:&#xD;
&#xD;
        -  Gastrointestinal toxicity grade ≥2;&#xD;
&#xD;
        -  Pelvic recurrence (radiotherapy volumes, mapping of recurrences).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pelvic recurrence-free survival (PRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pelvic recurrence-free survival (PRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>The PRFS is defined as the delay between randomization and pelvic recurrence or death, whichever occurs first. The pelvic recurrence will be evaluated according to RECIST V1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS is defined as the delay between randomization and tumor progression (local, regional, or distant) or death of any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>OS is defined as the delay between randomization and death, of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the delay between randomization and death, of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS)</measure>
    <time_frame>3 years</time_frame>
    <description>MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis-free survival (MFS)</measure>
    <time_frame>5 years</time_frame>
    <description>MFS is defined as the delay between randomization, and metastasis (clinical or radiological) or death of any cause whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>3 years</time_frame>
    <description>DSS is defined as the delay between randomization and death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival (DSS)</measure>
    <time_frame>5 years</time_frame>
    <description>DSS is defined as the delay between randomization and death due to bladder cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0</measure>
    <time_frame>5 years</time_frame>
    <description>The tolerance will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of Life</measure>
    <time_frame>5 years</time_frame>
    <description>The Bladder Cancer Index (BCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute and late toxicities</measure>
    <time_frame>5 years</time_frame>
    <description>The safety will be evaluated by toxicity: acute (&lt;6 months after RT) and late (≥6 months after RT), assessed using the NCI CTCAE Version N°4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Patients With High-risk MIBC</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Surveillance</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>pelvic radiotherapy</intervention_name>
    <description>adjuvant pelvic radiotherapy consisting of 28 x 1.8 Gy fractions (total dose of 50.4 Gy), 5 days per week, 1 fraction / day (duration of RT is 38 days).</description>
    <arm_group_label>Experimental Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible, the patients must fulfil all of the following inclusion criteria:&#xD;
&#xD;
          1. Patients with histologically-confirmed muscle-invasive bladder cancer, either with&#xD;
             pure urothelial carcinomas, or dominant urothelial carcinomas (&gt;50%) combined with&#xD;
             other histological variants including: micropapillary, epidermoid, or adenocarcinomas,&#xD;
             are eligible. Patients with small cell variants, pure adenocarcinomas, or pure&#xD;
             epidermoid carcinomas are not eligible.&#xD;
&#xD;
          2. Patients with radical cystectomy and pelvic lymph nodes dissection with no microscopic&#xD;
             residual disease (R0 and R1).&#xD;
&#xD;
             Note that only R1 patients without urinary diversion as orthotropic neo-bladder&#xD;
             replacement are eligible for the study, to limit cystectomy bed radiation induced&#xD;
             toxicities.&#xD;
&#xD;
          3. Patients with tumours of TNM staging: pN0-2, M0 by imagery, and pT3a, pT3b, pT4a, and&#xD;
             pT4b, as well as, pTX-pN1-2, pTX-NX-R1 are eligible.&#xD;
&#xD;
          4. Patients having received neo-adjuvant or adjuvant chemotherapy treatment are eligible.&#xD;
             Randomization is allowed only if AE due to chemotherapy are ≤grade 2 at randomization.&#xD;
&#xD;
          5. Patients ≥18 years old.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤2.&#xD;
&#xD;
          7. Absolute neutrophil count (ANC) ≥1500 cells/mm³.&#xD;
&#xD;
          8. Platelets ≥100000 cells/mm³.&#xD;
&#xD;
          9. Haemoglobin ≥8 g/dL (Note: following a blood transfusion or another intervention if&#xD;
             required).&#xD;
&#xD;
         10. Adequate hepatic function: aspartate aminotransferase (ASAT) and alanine&#xD;
             aminotransferase (ALAT) ≤2.5 x upper limit of normal (ULN); or ≤3.5 x ULN in the case&#xD;
             of concurrent disease with known etiology and for which a corrective treatment is&#xD;
             possible.&#xD;
&#xD;
         11. Adequate renal function: clearance &gt;30 mL/min (MDRD).&#xD;
&#xD;
         12. Patients having provided written informed consent prior to any study-related&#xD;
             procedures.&#xD;
&#xD;
         13. Patients affiliated to the social security scheme.&#xD;
&#xD;
         14. Patients willing and able to comply with the scheduled visits, treatment plan,&#xD;
             laboratory tests, and other study procedures indicated in the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patient must not be enrolled if he/she fulfils any of the following non-inclusion criteria:&#xD;
&#xD;
          1. Patients with R1 resection and with orthotropic neo-bladder reconstruction as urinary&#xD;
             diversion are not eligible.&#xD;
&#xD;
          2. Patients with clinical or radiological evidence of metastases or N3 staged bladder&#xD;
             cancer are not eligible.&#xD;
&#xD;
          3. Prior invasive solid tumours or haematological malignancies unless disease free for a&#xD;
             minimum of 3 years prior to randomisation except:&#xD;
&#xD;
               -  skin basal cell carcinoma,&#xD;
&#xD;
               -  in situ epithelioma of the cervix,&#xD;
&#xD;
               -  or prostate cancer: incidentally discovered during cystoprostatectomy and pelvic&#xD;
                  lymph node dissection and with a good prognosis (T stage &lt;pT3b and/or Gleason &lt;8&#xD;
                  and pN- and/or post-operative prostate-specific antigen (PSA) &lt;0.1 nanogram/mL),&#xD;
&#xD;
          4. Prior pelvic radiotherapy.&#xD;
&#xD;
          5. Patients with active inflammatory bowel disease.&#xD;
&#xD;
          6. Patients who required surgical treatment for bowel obstruction before bladder cancer&#xD;
             diagnosis or after cystectomy.&#xD;
&#xD;
          7. Prior chemotherapy for other malignant diseases within the previous 5 years, except&#xD;
             for neoadjuvant pre-cystectomy chemotherapy or adjuvant chemotherapy which are&#xD;
             permitted.&#xD;
&#xD;
          8. Patients with the following severe acute co-morbidity are not eligible:&#xD;
&#xD;
               -  Unstable angina or congestive heart failure that required hospitalization in the&#xD;
                  6 months before randomisation.&#xD;
&#xD;
               -  Transmural myocardial infarction in the 6 months prior to randomisation.&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at&#xD;
                  randomisation.&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy at the time of&#xD;
                  randomisation.&#xD;
&#xD;
               -  Severe hepatic disease: Child-Pugh Class B or C hepatic disease.&#xD;
&#xD;
               -  Known acquired immune deficiency syndrome (AIDS); the study treatment could&#xD;
                  impact blood count.&#xD;
&#xD;
          9. Patients with any other disease or illness which requires hospitalization or is&#xD;
             incompatible with the study treatment are not eligible.&#xD;
&#xD;
         10. Patients unable to comply with study obligations for geographic, social, or physical&#xD;
             reasons, or who are unable to understand the purpose and procedures of the study.&#xD;
&#xD;
         11. Patients enrolled in another therapeutic study within 30 days prior of randomisation.&#xD;
&#xD;
         12. Person deprived of their liberty or under protective custody or guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul SARGOS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stéphane LARRE, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Robert Debré</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Géraldine PIGNOT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mallik ZIBOUCHE</last_name>
    <phone>+ 33 1 44 23 55 68</phone>
    <email>m-zibouche@unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique de L'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentine GUIMAS, MD</last_name>
      <phone>+33 2 40 67 99 00</phone>
      <email>valentine.guimas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Générale d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul SARGOS, MD</last_name>
      <phone>+ 33 5 56 33 33 76</phone>
      <email>P.Sargos@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur Cfro</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ali HASBINI, MD</last_name>
      <phone>+33 2 98 31 32 00</phone>
      <email>alihasbini@oncologie-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER, MD</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>e.meyer@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hopital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne MARTIN, MD</last_name>
      <phone>+33 3 80 73 75 18</phone>
      <email>emartin@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier VERRY, MD</last_name>
      <phone>+33 4 76 76 54 35</phone>
      <email>cverry@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David PASQUIER, MD</last_name>
      <phone>+33 3 20 29 51 44</phone>
      <email>d-pasquier@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre CLAVERE, Prof</last_name>
      <phone>+33 5 55 05 62 69</phone>
      <email>pierre.clavere@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Bretagne Sud</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume BERA, MD</last_name>
      <phone>+33 2 97 06 90 30</phone>
      <email>g.bera@ghbs.bzh</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale POMMIER, MD</last_name>
      <phone>+33 4 78 78 51 66</phone>
      <email>pascal.pommier@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier MURACCIOLE, MD</last_name>
      <email>xavier.muracciole@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe HENNEQUIN, Prof</last_name>
      <phone>+33 1 42 49 90 24</phone>
      <email>christophe.hennequin2@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine DURDUX, Prof</last_name>
      <phone>+33 1 56 09 34 02</phone>
      <email>catherine.durdux@.aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aphp Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Chp Saint-Gregoire</name>
      <address>
        <city>Saint Gregoire</city>
        <zip>35760</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier ARTIGNAN</last_name>
      <phone>+33 2 90 09 44 64</phone>
      <email>xartignan@vivalto-sante.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO - site René Gauducheau</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane SUPIOT, MD</last_name>
      <phone>+33 2 40 67 99 13</phone>
      <email>stephane.supiot@ico.unicacner.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, Prof</last_name>
      <phone>+33 4 77 91 71 04</phone>
      <email>nicolas.magne@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
      <phone>+33 5 31 15 54 30</phone>
      <email>graff-cailleaud.pierre@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor LATORZEFF, MD</last_name>
      <phone>+33 5 67 20 44 00</phone>
      <email>i.latorzeff@clinique-pasteur.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

